Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464426 | 0.86 | NTRK1 (0.36) | NTRK1PIM1ACVR1CCNCCDK8 | |
| SCHEMBL3465569 | 0.76 | CCNC (0.33) | NTRK1PIM1ACVR1CCNCCDK8 | |
| SCHEMBL3464970 | 0.74 | CCNC (0.32) | NTRK1PIM1ACVR1CCNCCDK8 | |
| SCHEMBL28176465 | 0.73 | SIRT3 (0.43) | NTRK1PIM1ACVR1CCNCCDK8 | |
| SCHEMBL4491546 | 0.72 | NTRK1 (0.37) | NTRK1PIM1ACVR1CCNCCDK8 | |
| SCHEMBL3466161 | 0.72 | MYC (0.31) | CCNCCDK8 | |
| SCHEMBL4767580 | 0.69 | PIM1 (0.37) | NTRK1PIM1ACVR1CCNCCDK8 | |
| SCHEMBL28182603 | 0.66 | KMT2A (0.38) | NTRK1PIM1ACVR1KDM4E | |
| SCHEMBL15991433 | 0.62 | SIRT3 (0.43) | NTRK1PIM1ACVR1CCNCCDK8 | |
| SCHEMBL16414368 | 0.61 | ALDH1A1 (0.36) | TRIM24TRIM33KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | NTRK1 1654/4885PIM1 4774/4885ACVR1 1309/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | NTRK1 1512/4885PIM1 4486/4885ACVR1 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.